NCT05913375招募中不适用
Stereotactic Management of Arrhythmia - Radiosurgery Treatment and Evaluation of Response in Ventricular Tachycardia
Maria Sklodowska-Curie National Research Institute of Oncology4 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2023年7月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 4
- 主要终点
- Efficacy of the treatment
研究概览
简要总结
Prospective single-arm study investigating the efficacy and safety of non-invasive cardiac radiosurgery for the treatment of ventricular tachycardia (VT) with reduced dose of radiation (20 Gy). The efficacy and safety outcome measures will be compared with historical control - patients treated within the SMART-VT study (NCT04642963) with a single dose of 25 Gy to test the hypothesis that reduced dose of radiation is similarly effective in terms of reduction of VT burden.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Patients with structural heart disease
- •Patients with implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with defibrillation (CRT-D)
- •Clinically symptomatic ventricular arrhythmia despite adequate treatment, with episodes of ventricular tachycardia occurring at least 3 times per month
- •At least one episode of monomorphic ventricular tachycardia recorded during an electrophysiological examination
- •Recurrent VT despite at least one previous failed attempt at percutaneous ablation or disqualification from this treatment method (eg, patients after percutaneous closure of patent foramen ovale, ventricular septal defect).
- •Persistent recurrence of VT despite adequate pharmacotherapy.
- •Informed consent of the patient to participate in the study.
排除标准
- •Premature ventricular contractions
- •Cardiac damage requiring inotropic treatment
- •Implantation of left ventricular assist device (LVAD)
- •Ventricular arrhythmia in the course of channelopathy
- •Reversible cause of VT
- •New York Heart Association (NYHA) stage IV heart failure
- •Myocardial infarction or cardiac surgery in the last 3 months.
- •Life expectancy less than 6 months
- •Polymorphic ventricular tachycardia
- •Pregnancy or breastfeeding
- •Substrate location that prevents safe radiotherapy (eg due to location relative to critical organs, or dose given during previous radiotherapy treatments).
- •Evidence of an active systemic, pulmonary or pericardial inflammatory process that has required systemic treatment in the past 6 months (eg disease-modifying drugs, steroids, immunosuppressants). Patients treated for sarcoidosis who are currently in remission on chronic immunosuppressive drugs, without current signs of an acute inflammatory process, may be included in the study.
- •Active, uncontrolled malignancy and/or chemo/immunotherapy in the past month or planned within the month following radioablation.
- •Lack of the informed consent
结局指标
主要结局
Efficacy of the treatment
时间窗: 6 months
Number of patients with a reduction of the number of ventricular tachycardia (VT) episodes by at least 50% within 6 months after the irradiation compared to the number of VT episodes within 6 months before the intervention (based on registration from ICD/CRT-D), including: * the number of high-energy discharges * number of low-energy discharges for VT that was treated with stereotactic radiotherapy (STAR)
次要结局
- Number of hospitalizations due to VT episodes(12 months)
- Long term treatment safety(12 months)
- Recurrences outside the irradiated area(12 months)
- Change in the need for antiarrhythmic drugs(12 months)
- Six-month survival without VT episodes(6 months)
- Number of patients with a 90% reduction in the number of ICD discharges(12 months)
- Evaluation of changes in the morphology of the heart in the ultrasound examination(12 months)
- Early treatment safety(3 months)
- Assessment of the intensity and dynamics of changes in biochemical parameters of myocardial damage.(12 months)
- Evaluation of complications and mortality, including cardiac mortality and emergency hospitalizations during post-treatment follow-up(12 months)
- Evaluation of changes in the left ventricular ejection fraction(12 months)
- Number of patients with complete elimination of ICD discharges(12 months)
- Assessment of compliance of the results of additional imaging with the results of EAM(3 months)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Stereotactic Management of Arrhythmia - Radiosurgery in Treatment of Ventricular TachycardiaVentricular TachycardiaNCT04642963Maria Sklodowska-Curie National Research Institute of Oncology11
招募中
1 期
Stereotactic Radiotherapy for Fatal Arrhythmiasarrhythmia, cardiac, abblation, stereotactic radiotherapy, radioablationD017180ventricular tachycardiaJPRN-jRCTs042230030Kawamura Mariko3
招募中
不适用
StereoTactic Arrhythmia Radiotherapy in the NetherLands no. 1Ventricular tachycardiaNL-OMON22142Amsterdam University Medical Centers6
招募中
2 期
Stereotactic Arrhythmia Radiotherapy in the Netherlands no. 2Ventricular tachycardiaNL-OMON51339Academisch Medisch Centrum12
已完成
2 期
Stereotactic Arrhythmia Radiotherapy in the Netherlands no. 1Ventricular tachycardiaheart rhythm disorderventricular arrhythmia10007521NL-OMON48498Academisch Medisch Centrum6